Committee ok's Schering-Plough's sugammadex

An FDA committee has unanimously recommended Schering-Plough's sugammadex for approval. The drug, which is being developed to reverse the effects of anesthesia used during surgery, allows doctors to reverse the depth of a patient's muscle relaxation within minutes. The FDA usually follows the committee's recommendation. The drug gained priority review in January.

Schering gained sugammadex in its massive $14.4 billion buyout of Organon one year ago. Sugammadex will be sold under the name Bridion if approved.

Related Articles:
FDA to give Schering program priority review. Report
Organon touts late-stage data for sugammadex. Report